Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.

Citation

• Janne, P. A., Wang, M., Camidge, D. R., Mitchell, P., Fang, J., Nian, W., . . . Yang, J. C. -H. (2022). Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.. Journal of Clinical Oncology, 40(16_suppl), 9015. doi:10.1200/jco.2022.40.16_suppl.9015

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.9015

Web Of Science Accession Number

Start Page

• 9015

End Page

• 9015

Volume

• 40

Issue

• 16_suppl

Place Of Publication

Abstract

UOW Authors

•   Brungs, Daniel

Publication Date

• 2022

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Janne, P. A., Wang, M., Camidge, D. R., Mitchell, P., Fang, J., Nian, W., . . . Yang, J. C. -H. (2022). Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.. Journal of Clinical Oncology, 40(16_suppl), 9015. doi:10.1200/jco.2022.40.16_suppl.9015

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.9015

Web Of Science Accession Number

Start Page

• 9015

End Page

• 9015

Volume

• 40

Issue

• 16_suppl

Place Of Publication